This is a multicenter, Phase 2, Proof-of-concept study in subjects with newly diagnosed
glioblastoma multiforme (GBM).
All subjects will receive standard of care therapy for the treatment of their GBM and any
Anti-Epileptic Drug (AED) deemed necessary for their surgical resection of the GBM. Patients
who are taking concomitant AEDs will be eligible for the study. Treatment with Anhydrous
Enol-Oxaloacetate will be added to the Standard of Care.
This study is testing adjuvant Anhydrous Enol-Oxaloacetate (AEO) in GBM, an orally active
drug candidate which in animal studies has demonstrated decreased tumor growth rate and
increased survival.